Moss Genomics Completes Private Placement, Acquires 160 Ethereum

Moss Genomics Inc., a biotechnology company based in Vancouver, British Columbia, has recently announced the successful closure of a private placement, acquisition of 160 Ethereum cryptocurrency (ETH), and the appointment of a new member to its board of directors. The company raised a total of $250,000 through the private placement of 2,500,000 common shares. Simultaneously, Moss acquired 160 ETH in exchange for the issuance of 7,840,000 common shares. These transactions are pending final approval from the Canadian Securities Exchange, and all securities issued will be subject to a statutory hold period.

Hunter Jordan, a Vice President at a private real estate firm with extensive experience in global real estate operating company investments, has been appointed to Moss Genomics’ Board of Directors. Jordan’s background in strategic governance and expertise in scaling platforms will be a valuable addition to the company’s leadership team. Moss Genomics has also granted 200,000 stock options to several directors, officers, and consultants, each exercisable to purchase one common share at a price of $0.20 for a period of five years.

Moss Genomics Inc. is a forward-thinking biotechnology company that leverages Artificial Intelligence, Genomic, Microbiome, and various health data to develop innovative health solutions. By integrating blockchain technology and advanced treasury strategies, Moss aims to harness the latest technological advancements in the life sciences industry. For more information about Moss and its operations, interested individuals can visit the company’s website at mossgenomics.com or access the SEDAR+ profile at www.sedarplus.ca. For direct inquiries, Moss Genomics Inc. can be contacted via email at [email protected] or by phone at 604-710-0124.

It is important to note that the securities issued by Moss Genomics Inc. have not been registered under the U.S. Securities Act and are not available for sale in the United States unless in compliance with registration requirements or exemptions. This press release does not serve as an offer to sell securities or solicitations to buy them in any jurisdiction where such activities are deemed unlawful. The Canadian Securities Exchange and its Market Regulator hold no responsibility for the accuracy or adequacy of the information provided in this release.

Moss Genomics Inc.’s recent developments underscore its commitment to advancing biotechnological solutions and expanding its presence in the global market. The addition of Hunter Jordan to the company’s leadership team, along with the successful private placement and blockchain acquisition, position Moss as a key player in the evolving landscape of biotechnology and healthcare innovation. With a focus on leveraging cutting-edge technologies and strategic partnerships, Moss Genomics is poised to make significant strides in the realm of health science.